Charlotte Grieco,Tej Pandya,Charles Swanton
Charlotte Grieco
Over several decades, therapeutic advances have transformed oncology, yet for many tumour types, survival improvements have been incremental, with substantial treatment-related morbidity. A decisive pivot in oncology, from treating establis...
Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2-COL3A1 axis [0.03%]
衔接蛋白CIN85通过Akt/mTOR和MMP2-COL3A1轴增强成骨肉瘤细胞的运动能力
Iryna Horak,Iva Staniczková Zambo,Matěj Přikryl et al.
Iryna Horak et al.
Osteosarcoma is the most common malignant bone tumor, primarily affecting adolescents and young adults. Patients with metastases have a low survival rate, making the identification of prognostic markers crucial. The adaptor protein CIN85 is...
Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance [0.03%]
转移按暂停：肿瘤细胞如何在肿瘤微环境中保持休眠并逃避免疫监视
Kanishka Tiwary,Jose Javier Bravo-Cordero
Kanishka Tiwary
Metastasis remains the leading cause of cancer-related mortality. Even after major advances in early detection and systemic therapies, long-term disease recurrence frequently arises from the presence of dormant disseminated tumor cells (DTC...
Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer [0.03%]
蛋白酶体抑制剂伊沙佐米通过阻止拓扑异构酶Ⅰ降解逆转结直肠癌患者对伊立替康的抗性作用
Yuho Ebata,Koji Ando,Hirofumi Hasuda et al.
Yuho Ebata et al.
Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge. We previously showed that camptothecin induces ubiquitin-proteasome pathway (UPP)-mediated topoI degra...
Inés Paniagua,Johanna A Joyce
Inés Paniagua
Long-lived and large-bodied organisms face an inherent challenge: The more cells they contain and the longer they live, the greater the cumulative risk of acquiring mutations that can drive cancer. Yet, paradoxically, cancer incidence does ...
Revisiting Mission-Oriented Cancer Research to tackle the increasing burden of cancer in Europe-a policy perspective [0.03%]
从政策角度重新审视以任务为导向的癌症研究以应对欧洲日益加重的癌症负担
Manuel Heitor,Julio Celis,Ulrik Ringborg
Manuel Heitor
Cancer as the second leading cause of death in Europe poses an escalating challenge that needs urgent action. Translational cancer research should be the primary focus for addressing the increasing cancer burden in Europe and counteracting ...
Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy [0.03%]
HS1BP3与Cortactin的相互作用通过调节TKS5定位、细胞分泌和癌症恶性来发挥作用
Arja Arnesen Løchen,Kristiane Søreng,Chiara Veroni et al.
Arja Arnesen Løchen et al.
The HCLS1-Binding Protein 3 (HS1BP3) interacts with the SH3 domain of cortactin (CTTN), a protein that contributes to a malignant phenotype in cancers. Here, we demonstrate that high expression of HS1BP3 is associated with reduced survival ...
Differential expression of cancer-related genes supports prediction of poor response to first-line treatments in T-ALL pediatric patients with high minimal residual disease [0.03%]
癌症相关基因的差异表达支持了高最小残余病儿童T细胞急性淋巴细胞白血病患者对一线治疗反应不佳的预测能力
Antonio Lahera,Laura Vela-Martín,Pablo Fernández-Navarro et al.
Antonio Lahera et al.
T-cell acute lymphoblastic leukemia (T-ALL) originates from the malignant transformation of immature lymphoblasts committed to the T-cell lineage. Relapsed or refractory T-ALL patients show a dismal outcome with limited therapeutic options ...
Correction to "Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer" [0.03%]
对“ATG16L1剪接改变介导非小细胞肺癌中EGFR酪氨酸激酶抑制剂获得性抗性的机制”的校正
Published Erratum
Molecular oncology. 2026 Mar 27. DOI:10.1002/1878-0261.70247 2026
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer [0.03%]
通路在乳腺癌干细胞属性和耐药中的作用
Giulia Schiavoni,Antonella Palmese,Stefano Scalera et al.
Giulia Schiavoni et al.
Breast cancer, the most frequently diagnosed cancer in women globally, is a heterogeneous disease with distinct subtypes requiring distinct therapeutic approaches. Regardless of molecular subtyping, breast cancer stem cells significantly co...